Zurcher Kantonalbank Zurich Cantonalbank Has $196,000 Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 20.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,178 shares of the company’s stock after purchasing an additional 2,102 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Deciphera Pharmaceuticals were worth $196,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its stake in Deciphera Pharmaceuticals by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock valued at $169,000 after purchasing an additional 2,649 shares in the last quarter. Diversified Trust Co acquired a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at approximately $193,000. Aigen Investment Management LP bought a new stake in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $181,000. Finally, Cornercap Investment Counsel Inc. raised its holdings in Deciphera Pharmaceuticals by 24.6% during the 4th quarter. Cornercap Investment Counsel Inc. now owns 16,673 shares of the company’s stock worth $269,000 after buying an additional 3,294 shares during the period. 70.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on DCPH. Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $9.00 to $26.00 in a report on Tuesday, April 30th. JPMorgan Chase & Co. upped their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Jefferies Financial Group restated a “hold” rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. Stifel Nicolaus upped their price objective on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, Jonestrading reissued a “hold” rating and issued a $25.60 price objective on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $24.17.

Deciphera Pharmaceuticals Stock Up 0.0 %

NASDAQ:DCPH opened at $25.38 on Wednesday. Deciphera Pharmaceuticals, Inc. has a 12-month low of $9.90 and a 12-month high of $25.47. The stock’s 50 day moving average price is $16.91 and its two-hundred day moving average price is $15.07. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.08 and a beta of 0.20.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business had revenue of $48.30 million for the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter in the prior year, the business earned ($0.60) EPS. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. Equities research analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.